Combination of growth factors, cytokines, antibacterial/antiviral factors, stem cells factors, c3a/s4a complement proteins, immunoglobulins and chemotactic factors
SUBSTANCE: combination of cytokines, growth factors, chemotactic factors, stem cell factors, protein complement, immunoglobulins and antibacterial/antiviral factors, taken in a specific ratio and with a specific components composition for treatment of diseases, requiring reconstruction and regeneration of tissues. A pharmaceutical composition for treatment of diseases requiring restoration and regeneration of tissues.
EFFECT: combination described above and the pharmaceutical composition can effectively regenerate and restore tissues.
9 cl, 2 dwg, 11 tbl, 9 ex
SUBSTANCE: method involves the fasting oral administration of placenta hydrolysate 2ml in water 200 ml at a temperature of 37°C in the morning. After that, the patient is laid down on his/her back and exposed to infrared laser light generated by the laser scanning physiotherapeutic simulator SLSF-03.2 IK. An initial end face output power is 2 mW at a power flow density of 50 mW/cm2 on a projection of an ulcer defect on frame No. 57 or No. 59 with laser light modulation at a frequency of 12-15 a second for 3 minutes per one field. That is followed by exposing a projection of a bend of the elbow on frame No. 30 or No. 40 for 10 minutes per a field. Further, the patient stays in the same position to perform transcranial electric stimulation generated by the Doctor TES-03 apparatus. A gel forehead electrode (+) is applied in the middle of the forehead skin until adhered to the skin uniformly. Two gel postaural electrodes are applied on bony mastoid processes (-) until adhered to the skin uniformly. The electrodes are fixed with a headband. The exposure has a current intensity of 1.5 mA in the form of a bipolar pulsing frequency of 77.5 Hz for 20 minutes. The therapeutic course makes 10 daily procedures.
EFFECT: method provides reducing pain and dyspeptic syndromes, asthenovegetative syndrome, accelerating ulcerous process healing in the mucous membrane, achieving a stable remission, normalising the functional state of the adjacent organs, namely the liver, pancreas, reducing a desire to smoke up to a complete smoking cessation completely for the whole period of treatment.
4 tbl, 2 ex
SUBSTANCE: invention represents the method to obtain the soluble concentrate from sideline products of reindeer antlers, comprising aqueous raw extraction, grounded up to the forced meat condition with particle size of 3-5 mm under the action of ultrasonic vibrations with frequency of 37 kHz with subsequent filtration and vacuum drying at temperature of 45°C and pressure of 0.9 atm, distinguished by the fact that the aqueous raw extraction is carried out at temperature of 35-36°C in the presence of pepsin ferment at its concentration in raw mixture: water of 0.5% during at least 3 hours, at ratio raw: water for tails 1:5, for male genital 1:4, for uteruses with embryos and amniotic fluid 1:2.
EFFECT: significant increase of final concentrate yield from sideline products of reindeer antlers.
3 ex, 2 tbl
SUBSTANCE: invention refers to medicine, particularly to a method for active substance (AS) delivery through an epidermal barrier. The declared method involves using a matrix-type transdermal patch containing a substrate, a protective tape and a polymer layer, and characterised by the fact that 10% PEG-12 dimethicone niosomes are introduced into the polymer layer of the transdermal patch; then the substrate is coated with the polymer layer. The ACs are encapsulated into the niosomes with the use of hemogeniser APV, as well as 10 wt % propylene glycol and 5 wt % isopropyl myristate.
EFFECT: improving the active substance penetration with maintaining the biological activity and prolonging the active substance action.
2 tbl, 3 ex
SUBSTANCE: group of inventions relates to field of veterinary. Claimed method includes obtaining antiplacental blood (APB) from young healthy horse 14 days after subcutaneous double introduction of placentolysate of cows, which contains parts of cotyledons and caruncles, with 14-day interval in dose 20 ml, and method of treatment and prevention of afterbirth retention, uterus subinvolution and postnatal endometritis in cows by application of antiplacental blood (APB), stimulating postnatal involution of genitals of newly calved cows, which is introduced subcutaneously in the area of neck two times in dose 10 ml, with 6 day interval.
EFFECT: application of antiplacental blood (APB) reduces duration of postnatal involution of genitals, which makes it possible to prevent and reduce terms of treatment of ill cows in case of afterbirth retention, uterus subinvolution and postnatal endometritis.
SUBSTANCE: using the human placental perfusate cells in preparing a therapeutic agent for suppressing tumour cells proliferation in an individual having the tumour cells, wherein the placental perfusate cells represent a collection of nuclear cells of the placental perfusate. Using natural killer cells of CD56+, CD16- recovered from the placenta for preparing the therapeutic agent for suppressing the tumour cells proliferation in the individual having the tumour cells. Using the combined natural killer cells in preparing the therapeutic agent for suppressing the tumour cells proliferation in the individual having the tumour cells, wherein the above combined natural killer cells comprise the natural killer cells recovered from the placental perfusate, and the natural killer cells recovered from the umbilical blood, and wherein the umbilical blood is recovered from the placenta, which is used to prepare the above placental perfusate. A method for suppressing the tumour cells proliferation in vitro, involving the tumour cells contact to the human placental perfusate cells, wherein the placental perfusate cells represent the collection of the nuclear cells from the placental perfusate. The method for suppressing the tumour cells proliferation in vitro, involving the tumour cell contact to the number of the natural killer cells prepared of placental CD56+, CD16-. The method for suppressing the tumour cells proliferation in vitro, involving the tumour cells contact to the combined natural killer cells, wherein the above combined natural killer cells involve the natural killer cells recovered from the placental perfusate, and the natural killer cells recovered from the umbilical blood, and wherein the umbilical blood is recovered from the placenta, which is used for prepare the above placental perfusate. A composition applicable in suppressing the tumour cells proliferation, containing the recovered natural killer cells of CD56+, CD16-, wherein the above natural killer cells are recovered from the placental perfusate, and wherein the above natural killer cells make at least 50% cells in the composition.
EFFECT: placental perfusate cells and methods for using them enable suppressing the tumour cells proliferation effectively.
40 cl, 13 tbl, 6 ex, 11 dwg
FIELD: veterinary medicine.
SUBSTANCE: method comprises administering an agent containing gentamicin, gamavit, sodium benzoate, potassium sorbate and propylene glycol. The agent is used in intrauterine mode 2 times a day for 7-10 days at a dose of 5-10 ml to cat and 10-20 ml to dog.
EFFECT: method comprises high therapeutic efficacy in endometritis of cats and dogs.
FIELD: veterinary medicine.
SUBSTANCE: ferroglyukin is administered to new-born calves with iron deficiency anaemia at a dose of 150 mg (2 ml) intramuscularly, twice with an interval of 4 days. Crezacyne 5 mg/kg per day is included in the watering scheme for 4 days, starting simultaneously with the first injection of ferroglyukin. Gamavit is administered intramuscularly once a day in the morning at a dose of 0.05 ml/kg for 4 days, starting simultaneously with ferroglyukin and crezacyne.
EFFECT: method enables to normalise consistently the platelet activity in new-born calves with iron deficiency anaemia during a short period of exposure, transferring it to the level typical of healthy calves, after 4 days of treatment, and to provide long-term maintenance of platelet haemostasis in the optimal mode of operation, eliminating the risk of thrombotic complications in animals and contributing to their normal growth and development.
SUBSTANCE: declared invention refers to veterinary science and aims at recovering the estrual cycling and fertility in cows suffering from hypo-ovarionism. The method involves single parenteral administration of the gonadotrophic preparation of a pregnant mare serum gonadotropin - folligon in a dose of 1,000 IU on the 7th day from the beginning of treatment with underlying pre-injections of 2.5% progesterone in a dose of 4 ml, on the 1st, 3rd and 5th days of the therapeutic course, 2% Sinestrol in a dose of 2 ml on the 1st and 3rd days, and Eleovit in a dose of 5 ml on the 1st and 7th day of treatment.
EFFECT: declared invention provides normalising the hormonal-metabolic status and the recovered functional ovarian activity in the cows.
2 tbl, 2 ex
SUBSTANCE: placenta hydrolyzate 1 ml mixed with lanolin 30 g before the procedure is applied on an anterior abdominal wall of a patient lying on his/her back in the projection of adhesions. That is followed by phonophoresis generated by UZT-1.07F ultrasonic therapeutic apparatus and sounded by an emitter of the diameter of 4 cm of the intensity of 0.4-0.6 W/cm2. The exposure mode is continuous; an emitter velocity is 1-1.5 cm/sec. The length of procedure is 5-7 minutes. The therapeutic course is 10 procedures.
EFFECT: reduced progression of abdominal adhesions and their manifestations by evident anti-inflammatory effect, reduced pain syndrome, higher adaptive body reserves.
3 tbl, 2 ex
SUBSTANCE: allogenic multipotent mesenchymal stromal cells in the number of 6 million cells/kg are introduced intravenously in a dose of 3.0 Gy into rats suffered from radiation exposure. Additionally, haemopoietic stem cells recovered from umbilical blood in the number of 300 thousand cells/kg are introduced. The cells are transplanted in such a manner 60 min after radiation exposure.
EFFECT: higher mitosis count that leads to a substantial cryptal epithelium increase.
SUBSTANCE: group of inventions refers to veterinary science and is applicable for treating bovine mastitis. What is declared is a nosode for producing a preparation for treating bovine mastitis. That involves taking mastitis milk 1 ml with clinical signs of purulent-catarrhal mastitis, filling it 70° alcohol 9 ml to produce a homogenous solution; the produced solution is diluted to "Д6" with 70° alcohol. What is also declared is a preparation for treating bovine mastitis containing an aqueous-alcoholic solution of components. The components are Belladonna, Sulphur, Apis mellifica, Conium, Phytolacca, Silicea and above nosode in the following proportions, wt %: Belladonna - 5, Sulphur - 20, Apis mellifica - 20, Conium - 10, Phytolacca - 10, Silicea - 5, nosode - 15, aqueous-alcoholic solution up to 100%. What is also declared is a method of treating bovine mastitis involving the intracisternal administration of the preparation. The preparation is administered in a dose of 5-10 ml per 1 animal once a day.
EFFECT: declared group of inventions is highly effective in treating bovine mastitis.
3 cl, 5 tbl, 1 ex
SUBSTANCE: method of obtaining recombinant human lactoferrin, free of lipopolysaccarides, includes ion-exchange chromatography of transgenic goats on strong cation-exchanger, carrying sulphopropyl groups, elution of lactoferrin in sodium chloride gradient, desalination, with the following application of step-by-step washing of sorbent with sodium acetate buffer, which contains sodium chloride and ethanol in order to remove lipopolisaccharides, bound with lactoferrin, freeze-drying under specified conditions.
EFFECT: method makes it possible to obtain recombinant human lactoferrin, free of lipopolysaccharides.
SUBSTANCE: invention refers to medicine, namely to psychiatrics and neurology, and concerns treating epilepsy. That is ensured by administering antiepileptic preparations and immunomodulators; the immunomodulators are presented by natural oral transfer factors 'Transfer Factor' or 'Transfer Factor Advanced'. The transfer factors are administered in age daily doses depending on the clinical encephalographic values: maximum dosages, namely: into the children under 3 years of age - 800-1,000 mg/day, 3-7 years old - 1,000-1,200 mg/ day, 7-10 years old - 1,200-1,500 mg/day, aged 10 years and older and adults - 1,500-1,800 mg/day, are indicated for the patients with the current epileptic process for 6 months after the last clinically recorded attack; moderate dosages, namely: into the children under 3 years of age - 600-800 mg/day, 3-7 years old - 800-1,000 mg/ day, 7-10 years old - 1,000-1,200 mg/day, aged 10 years and older and adults - 1,200-1,500 mg/day, are used if observing clinical remission min. 1 year long; the support dosages, namely: into the children under 3 years of age - 400-600 mg/day, 3-7 years old - 600-800 mg/ day, 7-10 years old - 800-1,000 mg/day, aged 10 years and older and adults - 1,000-1,200 mg/day are administered for 3 years; if observing long-lasting remission, seasonal course prevention is initiated in dosages into the children under 3 years of age - 200-400 mg/day, 3-7 years old - 400-600 mg/ day, 7-10 years old - 600-800 mg/day, aged 10 years and older and adults - 800-1,000 mg/day; the transfer factors in the maximum or moderate dosages are used in intercurrent diseases or psychophysical overloads.
EFFECT: method provides the effective treatment of various forms of epilepsias with reducing side effects and reducing doses of the antiepileptic preparations.
1 tbl, 4 ex
SUBSTANCE: group of inventions relates to field of therapy and/or prevention of diseases in mammals, in particular humans. Group of inventions includes medication for treatment and/or prevention of cardiovascular disease, and/or inflammatory disease, and/or liver disease, and/or neurological disease, and/or steatosis by increasing content of polyunsaturated fatty acids in mammal's blood, representing dairy product of ruminants with reduced cholesterol content, where cholesterol content constitutes from 10 mg/100 g of fat to 150 mg/100 g of fat, as well as application of dairy product of ruminants with reduced cholesterol content, in which cholesterol content constitutes from 10 mg/100 g of fat to 150 mg/100 g of fat, for treatment and/or prevention of cardiovascular disease, and/or inflammatory disease, and/or liver disease, and/or neurological disease, and/or steatosis by increasing content of polyunsaturated fatty acids in mammal's blood.
EFFECT: obtaining medication for treatment and/or prevention of cardiovascular disease, and/or inflammatory disease, and/or liver disease, and/or neurological disease, and/or steatosis.
18 cl, 5 tbl, 1 ex
SUBSTANCE: invention can be used for the nutritive correction of the morphofunctional state of sportsmen at the stages of a training and competitive cycle (TCC). That is ensured by supplying the basic food intake with multi-component natural concentrated food substances (NCFSs) rich in biologically active substances (BASs) of herbal (HNCFSs) and/or protein and herbal (PHNCFSs) with consideration for solving the problems of the nutritional support in sportsmen of various sports according to the peculiarities of their professional athletic performance at the specific stages of the TCC.
EFFECT: preventing the developing prenosological and pathological states in the sportsman, achieving the high performance and stably high sports results.
2 cl, 3 tbl, 2 ex
SUBSTANCE: invention refers to medicine and can be used for reducing an individual's biological age. That is ensured by administering the Transfer-factor immune corrector 5 times a week for at least 6 weeks in a dose of 3-10 capsules a day in a combination with the hypoxic exposure in a cyclic-fractionation mode according to the scheme individually prescribed by the Stange's test results.
EFFECT: using this method provides reducing the age-related changes in the individuals by recovering a high level of tissue self-maintenance and optimising the body system functions that enables reducing the biological age by 9 years on the average.
2 cl, 2 tbl, 4 ex
FIELD: food industry.
SUBSTANCE: inventions group relates to medicine, in particular, to threpsology and may be used for children alimentation to increase bone mass density and/or to increase bone mineral content as well as to prevent osteoporosis and/or osteopenia. For this purpose one administrates the nutritive composition including 10-50 wt % of vegetal lipids (in terms of the composition dry weight) contained in lipid globules with a diameter equal to 2-12 mcm in an amount of at least 45 vol % in terms of full lipids volume.
EFFECT: said inventions usage allows to increase bone mineral contents and bone tissue density at a later age.
15 cl, 8 tbl, 5 ex
FIELD: veterinary medicine.
SUBSTANCE: method comprises giving to calves to drink the tincture of the combination herbal medicinal product - the grass of St. John's wort, meadowsweet, common yarrow, common nettle, rhizome of leather bergenia, root and rhizome of marsh cinquefoil, Scotch pine needles. At that the tincture fermented with microorganisms "EM Kurung" is used. The tincture is prepared by mixing 200 ml the tincture of the combination herbal medicinal product with 40 ml of the finished product "EM Kurung" and maintaining at the temperature of 18-20°C during the day, followed by filtration. EM-preparation "Baikal EM 1" is given to dry cows for 30 days prior to calving as a single dose in a dose of 30 ml/head. Mixoferon, sedimin and nitamin are additionally prescribed to new-born calves according to the following schedule: from the second feeding the tincture of the combination herbal medicinal product is watered with colostrum, fermented with microorganisms of EM-preparation "EM Kurung" at a dose of 150 ml/head dualfold for 10 days. On the 1, 2 and 8 day of life, mixoferon is injected intramuscularly at a dose of 9 ml/head. On the 1 and 8 day of life - nitamin and sedimin at a dose of 4 ml/head.
EFFECT: use of the claimed method enables to increase the immunobiological reactivity, energy of growth, provides prevention of gastrointestinal diseases of new-born calves.
4 tbl, 3 ex
FIELD: food industry.
SUBSTANCE: inventions group relates to food industry. The nutritive composition for improvement of the immune system with a mammal, preferably, with the human includes the following components: (a) at least 18 en% of protein material; (b) at least 12 wt % of leucine of the total quantity of protein material; (c) lipid fraction including at least one ω-3 polyunsaturated fatty acid chosen from the group consisting of eicosapentaenoic acid, docosahexaenoic acid, eicosatetraenoic acid and docosapentaenoic acid; (d) immunomodulator.
EFFECT: inventions group ensures intensification of protective immune response to an exogenous pathogene or autologous trigger such as neoplastic cells as well as improved humoral immunity or their combination.
17 cl, 4 dwg, 6 tbl, 6 ex
SUBSTANCE: invention relates to industrial microbiology, namely to a method of obtaining a composition, intended for prevention of a cow milk protein allergy (CMPA) and a higher sensitivity to allergens in newborn babies and infants. The method includes a stage of milk substrate bioconversion by means of a culture of Bifidobacterium breve BBC50 strain, deposited on May 31 1999 in the National Collection of Cultures of Microorganisms (CNCM) under the number I-2219, by keeping a substrate in contact with the strain culture under conditions unfavourable for production of an acid by the strain.
EFFECT: application of the claimed method makes it possible to obtain the composition, efficient for prevention of the allergy to cow milk proteins and a higher sensitivity to allergens in newborn babies and infants.
10 cl, 5 dwg, 1 ex
SUBSTANCE: invention relates to biotechnology of obtaining haemostatic medications. Claimed is method of separating purified fibrinogen concentrate, free of viruses and ballast proteins. Solubilisation of cryoprecipitate of fresh frozen human plasma is realised. Fibrinogen is precipitated with 20-30% PEG solution. Separated sediment is dissolved in buffer with sodium citrate and sodium chloride. Virus inactivation of solution by solvent-detergent method is carried out in presence of 1-3% Tween-80 and 0.1-1.5% of tri-n-butylphoshate. Obtained concentrate is purified from products of virus inactivation and solvent-detergents by triple extraction with liquid paraffin. After that, obtained fibrinogen concentrate is re-precipitated with 1.0-2.5 M glycine solution. Sterile filtration and lyophilic drying with further corking of lyophilisate under vacuum and thermal inactivation are performed.
EFFECT: invention makes it possible to obtained lyophilised form of fibrinogen concentrate with approximately 55% output.